Caribou Biosciences, Inc. (CRBU)
Market Cap | 449.37M |
Revenue (ttm) | 10.50M |
Net Income (ttm) | -111.20M |
Shares Out | 88.28M |
EPS (ttm) | -1.83 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,372 |
Open | 5.29 |
Previous Close | 5.26 |
Day's Range | 5.06 - 5.29 |
52-Week Range | 3.96 - 11.52 |
Beta | 1.94 |
Analysts | Strong Buy |
Price Target | 24.25 (+376.42%) |
Earnings Date | Nov 7, 2023 |
About CRBU
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refr... [Read more]
Financial Performance
In 2022, CRBU's revenue was $13.85 million, an increase of 44.31% compared to the previous year's $9.60 million. Losses were -$99.42 million, 48.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price forecast is $24.25, which is an increase of 376.42% from the latest price.
News

Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's pa...

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 tria...

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of a...

Caribou Biosciences offers more stock, and shares fall
Shares of Caribou Biosciences Inc. CRBU, +4.90% tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million share offering. The company, which focuses on genome e...

Caribou's cell therapy shows promise in early-stage cancer study
Caribou Biosciences Inc said on Thursday its experimental CAR T-cell therapy helped clear all signs or decrease tumor size in 94% of patients being treated for a type of cancer in the lymph nodes in a...

Caribou Biosciences Announces Proposed Public Offering of Common Stock
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has commenced...

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate,...

Pfizer Just Invested $25 million In This Biotech
Shares of Caribou Biosciences NASDAQ: CRBU were up 45% yesterday after Pfizer NYSE: PFE made a $25 million equity investment. On Thursday, the company said Pfizer bought almost 4.7 million shares of C...

Pfizer makes equity investment in Caribou Biosciences
Pfizer has invested $25 million to buy a minority stake in Caribou Biosciences , making it the latest small biotechnology firm to attract the pharmaceutical giant's interest.

Caribou Biosciences stock soars after Pfizer buys stock priced at a 31% premium
Shares of Caribou Biosciences Inc. CRBU ran up 21.3% toward a three-month high in premarket trading Thursday, after the genome-editing biopharmaceutical company said drug giant Pfizer Inc. has made a ...

Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
-- Pfizer purchases $25 million of Caribou common shares -- -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou's ...

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASDAQ: CRBU...

Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at...

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadin...

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models -- -- CB-012 IND-enabling studies ongoing; IND submission in r/r AML ...

CRBU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 11, 2023 in the Class Action Filed on Behalf of Caribou Biosciences, Inc. Shareholders
NEW YORK , April 11, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU) alleging that ...

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Caribou Investors of a Lead Plaintiff Deadline of April 11, 2023
NEW YORK , April 10, 2023 /PRNewswire/ -- Attention Caribou Biosciences, Inc. ("Caribou") (NASDAQ: CRBU) shareholders:

CRBU IMPORTANT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 11 Deadline in Securities Class Action - CRBU
NEW YORK , April 6, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or ...

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Caribou Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 11, 2023 - (NASDAQ: CRBU)
NEW YORK , April 5, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. Shareholders who purchased shares of CRBU during the class period l...

Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
-- CaMMouflage Phase 1 trial for CB-011 enrolling patients with r/r MM at dose level 1 -- BERKELEY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clini...

CRBU SHAREHOLDER ALERT: Jakubowitz Law Reminds Caribou Shareholders of a Lead Plaintiff Deadline of April 11, 2023
NEW YORK , March 31, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). To ...

CRBU LAWSUIT ALERT: Levi & Korsinsky Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , March 30, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit. CLASS ...

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
NEW YORK , March 24, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or ...

CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlie...

ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
NEW YORK , March 16, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or...